$48.64
2.42% yesterday
Nasdaq, Jun 30, 10:17 pm CET
ISIN
CH0334081137
Symbol
CRSP
Sector
Industry

CRISPR Therapeutics AG Target price 2025 - Analyst rating & recommendation

CRISPR Therapeutics AG Classifications & Recommendation:

Buy
62%
Hold
35%
Sell
3%

CRISPR Therapeutics AG Price Target

Target Price $80.58
Price $48.64
Potential
Number of Estimates 25
25 Analysts have issued a price target CRISPR Therapeutics AG 2026 . The average CRISPR Therapeutics AG target price is $80.58. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 34 analysts: 21 Analysts recommend CRISPR Therapeutics AG to buy, 12 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the CRISPR Therapeutics AG stock has an average upside potential 2026 of . Most analysts recommend the CRISPR Therapeutics AG stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 37.31 48.60
89.95% 30.26%
EBITDA Margin -1,198.90% -1,044.78%
2,095.58% 12.86%
Net Margin -981.64% -981.32%
2,272.21% 0.03%

28 Analysts have issued a sales forecast CRISPR Therapeutics AG 2025 . The average CRISPR Therapeutics AG sales estimate is

$48.6m
Unlock
. This is
28.98% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$150m 298.49%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $37.3m 89.95%
2025
$48.6m 30.26%
Unlock
2026
$179m 268.62%
Unlock
2027
$409m 128.24%
Unlock
2028
$887m 116.86%
Unlock
2029
$2.3b 157.58%
Unlock
2030
$6.1b 167.16%
Unlock
2031
$1.4b 77.79%
Unlock
2032
$1.7b 25.90%
Unlock

10 Analysts have issued an CRISPR Therapeutics AG EBITDA forecast 2025. The average CRISPR Therapeutics AG EBITDA estimate is

$-508m
Unlock
. This is
11.54% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-434m 4.59%
Unlock
, the lowest is
$-548m 20.29%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-447m 120.68%
2025
$-508m 13.51%
Unlock
2026
$-468m 7.77%
Unlock
2027
$-518m 10.55%
Unlock
2028
$-12.8m 97.52%
Unlock
2029
$258m 2,115.71%
Unlock

EBITDA Margin

2024 -1,198.90% 2,095.58%
2025
-1,044.78% 12.86%
Unlock
2026
-261.42% 74.98%
Unlock
2027
-126.62% 51.56%
Unlock
2028
-1.45% 98.85%
Unlock
2029
11.31% 880.00%
Unlock

30 CRISPR Therapeutics AG Analysts have issued a net profit forecast 2025. The average CRISPR Therapeutics AG net profit estimate is

$-477m
Unlock
. This is
23.66% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-345m 10.42%
Unlock
, the lowest is
$-568m 47.25%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-366m 138.43%
2025
$-477m 30.22%
Unlock
2026
$-393m 17.64%
Unlock
2027
$-310m 20.96%
Unlock
2028
$19.9m 106.40%
Unlock
2029
$565m 2,741.12%
Unlock
2030
$2.2b 284.14%
Unlock
2031
$334m 84.62%
Unlock
2032
$439m 31.56%
Unlock

Net Margin

2024 -981.64% 2,272.21%
2025
-981.32% 0.03%
Unlock
2026
-219.26% 77.66%
Unlock
2027
-75.93% 65.37%
Unlock
2028
2.24% 102.95%
Unlock
2029
24.72% 1,003.57%
Unlock
2030
35.54% 43.77%
Unlock
2031
24.62% 30.73%
Unlock
2032
25.72% 4.47%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -4.34 -5.52
123.71% 27.19%
P/E negative
EV/Sales 48.26

30 Analysts have issued a CRISPR Therapeutics AG forecast for earnings per share. The average CRISPR Therapeutics AG EPS is

$-5.52
Unlock
. This is
23.21% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-4.00 10.71%
Unlock
, the lowest is
$-6.58 46.88%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-4.34 123.71%
2025
$-5.52 27.19%
Unlock
2026
$-4.55 17.57%
Unlock
2027
$-3.60 20.88%
Unlock
2028
$0.23 106.39%
Unlock
2029
$6.54 2,743.48%
Unlock
2030
$25.11 283.94%
Unlock
2031
$3.86 84.63%
Unlock
2032
$5.08 31.61%
Unlock

P/E ratio

Current -10.86 46.73%
2025
-8.81 18.85%
Unlock
2026
-10.69 21.34%
Unlock
2027
-13.53 26.57%
Unlock
2028
211.38 1,662.31%
Unlock
2029
7.44 96.48%
Unlock
2030
1.94 73.92%
Unlock
2031
12.59 548.97%
Unlock
2032
9.57 23.99%
Unlock

Based on analysts' sales estimates for 2025, the CRISPR Therapeutics AG stock is valued at an EV/Sales of

48.26
Unlock
and an P/S ratio of
86.43
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 62.25 582.57%
2025
48.26 22.47%
Unlock
2026
13.09 72.87%
Unlock
2027
5.74 56.19%
Unlock
2028
2.65 53.89%
Unlock
2029
1.03 61.18%
Unlock
2030
0.38 62.57%
Unlock
2031
1.73 350.31%
Unlock
2032
1.37 20.58%
Unlock

P/S ratio

Current 111.48 560.46%
2025
86.43 22.47%
Unlock
2026
23.45 72.87%
Unlock
2027
10.27 56.19%
Unlock
2028
4.74 53.89%
Unlock
2029
1.84 61.18%
Unlock
2030
0.69 62.57%
Unlock
2031
3.10 350.35%
Unlock
2032
2.46 20.58%
Unlock

Current CRISPR Therapeutics AG Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Clear Street
Locked
Locked
Locked Jun 27 2025
HC Wainwright & Co.
Locked
Locked
Locked Jun 27 2025
Piper Sandler
Locked
Locked
Locked Jun 27 2025
JMP Securities
Locked
Locked
Locked Jun 27 2025
Chardan Capital
Locked
Locked
Locked Jun 26 2025
Needham
Locked
Locked
Locked Jun 26 2025
JMP Securities
Locked
Locked
Locked May 21 2025
Analyst Rating Date
Locked
Clear Street:
Locked
Locked
Jun 27 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jun 27 2025
Locked
Piper Sandler:
Locked
Locked
Jun 27 2025
Locked
JMP Securities:
Locked
Locked
Jun 27 2025
Locked
Chardan Capital:
Locked
Locked
Jun 26 2025
Locked
Needham:
Locked
Locked
Jun 26 2025
Locked
JMP Securities:
Locked
Locked
May 21 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today